October 1, 2010
Hyatt Regency Washington on Capitol Hill
Washington, D.C.
The primary audience for the 2010 Workshop included scientists and clinicians from regulatory agencies, industry, and academics who are interested in understanding more about monoclonal antibodies (mAbs). The Workshop facilitated interactive discussion on mechanisms of action responsible for clinical efficacy of monoclonal antibodies, mechanisms of resistance to monoclonal antibodies and how to best utilize current knowledge to develop more effective antibody-based cancer treatments.
Topics Included:
Organizers |
|
Glenn Dranoff, MD
Ira Mellman, PhD |
George J. Weiner, MD
|
View the 2010 iSBTc program supporters.